Life sciences stories
As India’s AI boom accelerates, investors are being urged to weigh trust, inclusion and long-term value alongside growth and scale.
A stronger FY26 lifted Persistent's dividend to INR 40 a share as annual revenue climbed 17.4%, with quarterly growth extending to a 24th straight quarter.
Business users could get governed AI support inside analytics workflows as SAS adds copilots, agents and open-standard connectors to Viya.
The drugmaker plans to spread AI across 75,000 staff, from research to manufacturing, as it seeks faster launches and leaner operations.
Early adopters are seeing stronger returns as AI agents move from trials into core operations across customer service, security and support.
Research teams could see faster target discovery as OpenAI opens GPT-Rosalind to qualified US customers for biology and drug discovery work.
Scientists without coding skills can now run AI-assisted drug design and wet-lab testing in one system, speeding early discovery.
A trust-backed board majority now gives Anthropic tighter oversight as it seeks to balance rapid AI growth with its public benefit mission.
The Danish quantum software firm is pushing into life sciences now, adding senior hires and partners to sell hybrid tools before the market matures.
Pharmaceutical field teams could cut hours of searching to seconds as ACTO's new system routes approved information through compliance checks.
Federal buyers of AI and HPC systems will gain wider access to Cornelis’s CN5000 platform through new partners ASI Corp, CTG Federal and TVAR Solutions.
Canada’s health tech sector is struggling to turn strong research into commercial scale, as panellists split over whether policy or private capital should lead.
A state-backed push to fund northern university spinouts has lifted Northern Gritstone’s capital base to GBP £382 million amid a tough fundraising market.
The five-year deal will give Swedish researchers and smaller firms cloud-style access to AI infrastructure as demand for Mimer grows.
Toronto will gain 27MW of new capacity in mid-2026 as Yondr enters Canada with a campus designed to curb water use and meet green standards.
The commitment could help Episode 1’s latest fund reach a first close and attract more private capital for early-stage UK start-ups.
The showcase highlighted early-stage ventures tackling clinical delays, relationship support and school safety as finalists pitched to investors and local firms.
The move gives UK life sciences firms a new source of scale-up capital as a funding gap has left many promising businesses short of backing.
The London biotech startup will use new funding to broaden deployments at major drugmakers, including Pfizer, and speed research decisions.
The investment firm is shifting towards regular portfolio realisations after two major sales, as Antonia Jenkinson takes over the finance brief.